{"schema_version":"secwatch.filing_event.v1","accession":"0001877322-23-000005","form_type":"8-K","ticker":"ESAB","cik":"0001877322","company_name":"ESAB Corp","filed_at":"2023-03-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.309613+00:00","generated_at":"2026-06-18T10:35:34.068810+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ESAB Q4 2022: diluted EPS $0.97, adj. EPS $1.05; sales +11% organic; guides 2023 EBITDA $420-440M","bullets":["Q4 2022 sales $664M (+6% reported, +11% organic); net income $59M.","Diluted EPS continuing ops $0.97; core adj. diluted EPS $1.05.","Core adj. EBITDA $107M, up 10% vs $98M prior year Q4.","Completed Swift-Cut and Therapy Equipment bolt-on acquisitions.","2023 guidance: core organic growth 3-5%; core adj. EBITDA $420-440M; core adj. EPS $3.80-$4.00."],"urls":{"canonical":"https://secwatch.observer/filing/0001877322-23-000005","json":"https://secwatch.observer/filing/0001877322-23-000005.json","markdown":"https://secwatch.observer/filing/0001877322-23-000005.md","text":"https://secwatch.observer/filing/0001877322-23-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1877322/000187732223000005/0001877322-23-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1877322/000187732223000005/esab-20230307.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T10:35:34.068810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"883841f001cefe78a8c5f4a09352c22ad0d72e17","claim":"ESAB Corp reported the fourth quarter ended December 31, 2022 results: revenue $664 million, net income $59 million, EPS $0.97 diluted earnings per share from continuing operations. Guidance initiated.","evidence_excerpt":"ESAB Corporation reported fourth quarter sales of $664 million, an increase of 6% on a reported basis or 11% higher core organic growth before acquisitions and currency translation impacts. ESAB also reported fourth quarter GAAP net income from continuing operations attributable to ESAB of $59 million, $0.97 diluted earnings per share from continuing operations and core adjusted net income of $64 million, $1.05 diluted per share.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1877322/000187732223000005/0001877322-23-000005-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$664 million"},{"label":"Net income","value":"$59 million"},{"label":"EPS","value":"$0.97 diluted earnings per share from continuing operations"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}